Provider, Patient, or Payer: Who Pays for Digital Health?

Digital health has four possible customers — providers, patients, payers, and employers — and they rarely overlap. The person who uses your product is usually not the person who pays for it. Pick one economic buyer to build for first, prove they will actually write a check, and treat the other three as later channels rather than a single blended market.

Quick Answer: In healthcare the user and the buyer split apart. Choose one economic buyer — provider, patient, payer, or employer — and validate that they will pay before you scale. Building for the wrong one is the most common way digital health startups quietly stall.

If you came from software, this is the part that breaks your instincts. In most SaaS, the person using the product and the person approving the invoice are close together, sometimes the same person. In healthcare they are almost never the same person, and the distance between them is where good products go to die. This guide maps the four buyers, shows how their economics differ, and gives you a way to validate demand against the right one before you commit a year of engineering to the wrong one.

Why buyer, user, and payer split in healthcare

The buyer, user, and payer split in healthcare because the person who benefits from a health product rarely controls the budget that funds it — and the person who controls the budget rarely feels the benefit directly. That structural gap is the defining feature of the industry, not an edge case.

Consider a remote monitoring tool for people managing a chronic condition. The patient uses it daily and feels the value. The provider may prescribe or recommend it and carries the clinical responsibility. The payer — an insurer or government program — may ultimately cover the cost if it reduces expensive downstream care. And an employer may be the one who purchases access on behalf of its workforce. Four different actors, four different definitions of "value," one product.

That fragmentation produces three problems you have to design around:

• Value flows to one party, cost lands on another. A tool that saves a payer money by preventing hospital visits may cost a provider time to set up. Whoever bears the cost has to be convinced the benefit is worth it — even when the benefit accrues elsewhere.
• Every buyer has a different definition of proof. A patient trusts a clean experience and a recommendation. A clinician trusts outcomes and peer usage. A payer trusts economic evidence. What counts as "enough proof to buy" is different in each lane.
• The sales motion is completely different in each lane. Consumer marketing, clinical sales, insurer contracting, and employer benefits procurement share almost nothing operationally. You cannot run one playbook across all four.

The temptation is to say "we serve everyone." In practice a blended market is not a market — it is four markets you are half-serving, and demand signals from one lane tell you nothing reliable about the others.

The user is not the buyer — and that changes what "demand" means

The single most important reframe is this: enthusiasm from users is not the same as demand from buyers. A patient loving your app is a necessary signal but not a sufficient one, because the patient may not be the one paying. When you test demand, you have to test it against whoever actually opens their wallet.

This is exactly where founders coming from consumer or B2B software get burned. They run a landing-page test, see strong sign-ups, and conclude the idea is validated. But sign-ups measure user interest, not buyer willingness to pay. In a B2B2C healthcare model, the person clicking "join the waitlist" and the entity signing the contract are two different validation experiments. If you want the full mechanics of running those experiments, the complete guide to customer research for founders breaks down how to separate user pull from buyer commitment. In healthcare, that separation is not optional.

The four digital health channels compared: provider, patient, payer, employer

The four channels differ most on three axes that decide your entire go-to-market: how long the sales cycle runs, the shape of the deal size, and how high the evidence bar sits before anyone commits. The table below compares them on exactly those axes so you can see why picking one changes everything downstream.

The takeaway: these are not four flavors of the same motion — they are four different businesses wearing the same product. A short consumer sales cycle rewards fast iteration and paid acquisition; a payer's long cycle rewards evidence generation and patience. Choosing your first buyer is really choosing what kind of company you are willing to build for the next two years.

Note that everything here is framed around the US market, where the buyer/payer split is especially pronounced. In single-payer and mixed systems elsewhere, the actors and evidence bars differ — verify how these channels map to your own market before you apply the table.

Selling to providers: how to validate clinical demand

Validate provider demand by confirming that a clinician or health-system decision-maker will change their workflow and budget for your product — not merely that they find it interesting in a demo. Clinical interest is cheap; workflow change is the real signal.

Providers buy things that make care better, safer, faster, or more profitable without adding friction to an already overloaded day. The fastest way to be rejected is to add clicks, add documentation, or add steps that pull attention away from the patient. So your validation has to test the workflow, not just the concept.

Concretely, look for these commitment signals rather than warm words:

• A named budget owner. Ask who would pay and from which budget. If no one can name the budget line, you are talking to a fan, not a buyer.
• Willingness to pilot with real conditions. A paid pilot, or an unpaid pilot with a written success metric and a decision date, beats an open-ended "let's try it."
• A workflow walk-through. Have them show you exactly where your product would sit in their day. If it does not fit, they already know, even if they are too polite to say so.

Two structural realities shape provider sales. First, the buyer and the user may differ even inside the organization — administrators may sign while clinicians use, and a product loved by clinicians can still be killed by administration, or vice versa. Second, clinical credibility compounds slowly. Providers are pragmatic buyers who look sideways at what their peers already trust before they commit; a lighthouse reference in one respected institution does more than any feature list.

This is the classic beachhead problem Geoffrey Moore describes in Crossing the Chasm: win one narrow, reference-able segment completely rather than being mildly appealing to everyone. In healthcare that beachhead is often a single specialty in a single type of setting — and getting there deliberately is a core part of validating a healthtech startup idea before you scale the sales team.

Selling to patients: how to validate direct-to-consumer demand

Validate direct-to-consumer demand by confirming that patients will pay their own money — not just sign up for free — for the specific outcome you deliver. In healthcare, "free interest" and "paid intent" are separated by a wider gap than in almost any other consumer category, because people expect health costs to be covered by someone else.

The direct-to-consumer lane looks the most like normal software: short decision cycles, marketing-driven acquisition, fast iteration. That familiarity is a trap. Patients paying out of pocket are a self-selected slice of the population — often those who can afford to, or who are underserved by covered options. Strong sign-up numbers can hide the fact that very few will convert to paid, and even fewer will stay.

So test money early. A landing page that measures email sign-ups tells you about curiosity. A pre-order, a paid waitlist deposit, or a live paywall in front of a working prototype tells you about intent. When you run customer research in this lane, weight the paid-conversion experiment far more heavily than the interest experiment, because interest is abundant and cheap while willingness to pay is scarce and decisive.

Two cautions specific to consumer health:

• Retention is the hidden killer. Health behavior change is hard, and many consumer health products see engagement fall off a cliff after the first few weeks. Validate that people come back, not just that they sign up.
• Trust and safety are part of the product. Consumers are wary about health data. Being visibly careful with data — and, where relevant, clear about clinical limits — is not overhead; it is a conversion factor.

Some consumer products eventually shift to being paid for by an employer or payer once they prove engagement. That is a legitimate path, but treat it as a second validation, not an assumption baked into your first one.

Selling to payers: how to validate reimbursement demand

Validate payer demand by testing whether your product can clear a rigorous economic and outcomes bar — and whether a real coverage or contracting path exists — long before you assume "insurance will pay for it." Payers are the highest-ceiling and slowest-moving buyer, and the mistake founders make is treating reimbursement as a switch that flips rather than a bar you have to clear.

Payers — private insurers and government programs — buy things that reduce their total cost of care or are required of them. Their evidence bar is the highest of any buyer because they are underwriting risk across large populations. A tool that "seems helpful" is not enough; they typically want credible evidence tying your product to reduced spending or improved measurable outcomes.

Before you build around a payer model, pressure-test these questions:

• Is there an established path for getting paid? Coverage decisions and billing pathways in the US are specific and slow to change. Understanding how reimbursement actually works — coverage determinations, billing mechanisms, and the evidence they hinge on — is foundational, not a detail to sort out later.
• What outcome would a payer actually pay to change? Payers care about the costly, common, and measurable. If the outcome you improve is none of those, the economic case will not close no matter how good the product is.
• Who is the actual contracting buyer? "Payers" is a category, not a customer. Different programs, plans, and regions have different policies and processes.

A caution on regulation and evidence, and one that is firmly US-centric: coverage rules, billing pathways, and the level of clinical evidence expected vary by program, by region, and over time. Do not build a business plan on a specific coverage rule, code, or threshold you half-remember — verify the current pathway with someone who does this professionally, and verify it for your specific market rather than assuming it generalizes.

Because the payer cycle is so long, many founders validate the payer thesis indirectly first: prove the outcome and the engagement through a provider or employer channel, generate the evidence there, and use that evidence to open the payer conversation from a position of proof rather than a pitch.

Selling to employers: how to validate benefits-buyer demand

Validate employer demand by testing whether a benefits leader will add your product to their offering for the coming plan year — which means proving both employee engagement and a plausible cost or productivity story. Employers sit between the consumer and payer worlds, and they are often the most overlooked buyer despite being one of the most accessible.

Employers who self-fund a meaningful share of their workforce's health costs behave a lot like payers: they are motivated to reduce spending and improve the health of their population. But their buying process is tied to benefits cycles and mediated by HR leadership and, frequently, benefits brokers or consultants who act as gatekeepers and advisors.

To validate this lane, look for:

• A benefits owner who will commit to a plan-year timeline. Employer buying often follows an annual rhythm; a real buyer can tell you the window and the decision process.
• The broker/consultant relationship. In many mid-to-large employers, you are not just selling to HR — you are being evaluated by an advisor whose recommendation carries weight. Validate whether that channel will carry you.
• An engagement story that survives contact with a real workforce. Employers have been burned by point solutions that nobody uses. A believable, evidenced engagement rate matters as much as the clinical claim.

The employer lane is attractive because deals are large and the sales cycle is shorter than a payer's, and because it can serve as the evidence-generating stepping stone toward a payer relationship later. The risk is the same "engagement cliff" that haunts consumer products: a benefit that employees sign up for and then abandon will not be renewed, no matter how strong the initial launch looked.

Common mis-targeting mistakes

The most common mis-targeting mistake is validating enthusiasm from the user while assuming the buyer will follow — and then discovering, months in, that the person who loved the product was never the person who pays for it. Nearly every stalled digital health startup can trace its stall to a mismatch between who was excited and who was invoiced.

Watch for these specific failure patterns:

• Mistaking user love for buyer demand. A delighted patient or clinician is a signal, not a sale. If you have not confirmed who pays and that they will, you have validated interest, not a business.
• Treating "healthcare" as one market. Blending providers, patients, payers, and employers into a single go-to-market spreads you across four sales motions and lets weak signals in one lane masquerade as validation for all four.
• Assuming reimbursement is coming. "Insurance will eventually cover this" is a hope, not a plan. Payer coverage is a bar to clear with evidence and a defined pathway, and it is US-market-specific — assuming it is a common way to run out of runway.
• Pricing to the wrong wallet. A price a patient would never pay out of pocket may be trivial to an employer or payer, and vice versa. Anchoring your price to the wrong buyer distorts every unit-economics assumption downstream.
• Skipping the workflow reality. Especially with providers, a product that adds friction dies regardless of how compelling the pitch is. If you did not validate the workflow, you did not validate the sale.

The correction for all five is the same discipline: name your economic buyer explicitly, design a validation test that requires that buyer to commit something real, and refuse to count user enthusiasm as a substitute. A tool like Edmired can help structure those buyer-specific experiments, but the underlying rule is one you enforce yourself — validate the wallet, not just the smile.

Key Takeaways

• The user and the buyer are usually different people in healthcare — sometimes three or four different actors — so demand must be validated against whoever actually pays, not whoever uses.
• There are four buyers, and each is a distinct business: providers, patients, payers, and employers differ on sales cycle, deal size, and evidence bar, and no single go-to-market motion works across all four.
• Pick one economic buyer first and win it completely before layering on the others — a narrow, reference-able beachhead beats being mildly appealing to everyone.
• Enthusiasm is not intent to pay — free sign-ups measure curiosity; pre-orders, paid pilots, and signed contracts measure the demand that actually funds a company.
• Payer reimbursement is a bar to clear, not a switch that flips — it demands rigorous evidence, a defined coverage pathway, and patience, and its specifics are US-market-dependent.
• Regulatory and coverage rules vary by market and change over time — treat any specific rule, code, or threshold as something to verify with a professional for your region, not to build a plan around.
• Employers are the underrated middle path — large deals, a shorter cycle than payers, and a natural stepping stone to generating the evidence a payer will later demand.

Frequently Asked Questions

Who is the real customer in a digital health startup?

The real customer is whoever pays for and can stop paying for your product — the economic buyer — which in healthcare is often not the user. Depending on your model that is a provider, an individual patient, a payer, or an employer. Identify that buyer first, because they define your sales cycle, your pricing, and your evidence bar.

Do I need insurance reimbursement to build a digital health company?

No. Many digital health companies succeed selling directly to patients, providers, or employers without payer reimbursement, and some pursue reimbursement only later once they have generated evidence. Reimbursement unlocks scale for certain models but carries a long cycle and a high evidence bar, and its rules are US-specific — treat it as one path among several, not a requirement.

How is validating a healthtech idea different from a normal startup?

The core difference is that user enthusiasm does not equal buyer demand, because the person using a health product is usually not the person paying for it. You have to run a separate validation experiment against the actual economic buyer, test whether your product survives real clinical or benefits workflows, and account for evidence and regulatory bars that most software never faces.

Should I sell to providers, patients, payers, or employers first?

Start with the buyer whose evidence bar you can clear soonest and whose sales cycle your runway can survive. For many founders that means patients or employers early — shorter cycles, faster proof — using that evidence to open slower, larger provider or payer conversations later. Choose one deliberately and win it fully before adding a second.

What is a B2B2C healthcare model?

A B2B2C healthcare model is one where you sell to a business — a provider, payer, or employer — that then delivers your product to the individual who uses it. You have two customers to satisfy: the business that pays and the person who uses it. Both must be validated separately, because a product the end user loves can still fail if the paying business sees no return.